-+ 0.00%
-+ 0.00%
-+ 0.00%

D. Boral Capital Maintains Buy on Citius Pharmaceuticals, Lowers Price Target to $6

Benzinga·06/10/2025 12:06:05
Listen to the news
D. Boral Capital analyst Jason Kolbert maintains Citius Pharmaceuticals (NASDAQ:CTXR) with a Buy and lowers the price target from $9 to $6.